Cancer Treatment News and Research

RSS

Romiplostim prevents chemotherapy-induced thrombocytopenia in phase 3 trial

Results from a global phase 3 clinical trial led by investigators at Mass General Brigham show that the medication romiplostim can effectively prevent chemotherapy from destroying platelet-producing bone marrow cells, a common complication known as chemotherapy-induced thrombocytopenia.

12 Mar 2026

Structured exercise helps chemotherapy patients maintain cognitive function and mental clarity

New research in the March 2026 issue of JNCCN-Journal of the National Comprehensive Cancer Network suggests that exercise may help people with cancer stay mentally sharp and better able to handle daily tasks, work, and social activities through chemotherapy treatment delivered on an every two-week cycle.

12 Mar 2026

Disrupting protein production in tumors triggers potent immune responses

A new study led by Pierre Close's team (GIGA, Laboratory of Cancer Signaling, and WELRI Investigator) reveals how subtly disrupting the way tumors produce their proteins can trigger a potent antitumor immune response.

11 Mar 2026

Microbial ecosystems influence success of cancer checkpoint immunotherapy

Immune checkpoint inhibitors targeting PD-1 and PD-L1 have revolutionized cancer therapy, delivering long-term survival benefits in several malignancies.

9 Mar 2026

Boron neutron capture therapy shows promise for deadly brain tumors

Malignant gliomas are among the deadliest brain cancers, with limited treatment options and poor survival.

9 Mar 2026

Ketone body can strengthen the fitness and antitumor activity of CAR T cells

A naturally occurring byproduct of liver metabolism–the ketone body, β-hydroxybutyrate (BHB)–can strengthen the fitness and antitumor activity of CAR T cells.

6 Mar 2026

Single dose of CAR-astrocyte therapy halves amyloid levels in mice brains

The new generation of Alzheimer's disease drugs - the first proven to change the course of the disease - typically extend independent living for patients by 10 months.

6 Mar 2026

MSK uncovers how interacting mutations shield breast cancer

Researchers at Memorial Sloan Kettering Cancer Center (MSK) have made an important discovery about how genetic mutations in breast cancer patients can interact and drive resistance to certain drugs called CDK4/6 inhibitors. This finding, published in Nature, suggests a new strategy for predicting and preventing resistance to specific therapies based on the tumor's genetic profile.

6 Mar 2026

A review of methionine dependency in modern cancer therapy

Methionine restriction (MR) has shown significant promise in cancer therapy because it targets the unique methionine dependency of many tumors. However, despite extensive research on MR, a clear synthesis of preclinical findings and their translation into clinical settings is lacking. This review aims to address this gap by consolidating existing evidence, identifying challenges, and highlighting opportunities for advancing MR as a viable cancer treatment strategy.

6 Mar 2026

Can brain training prevent dementia? Long-term trial shows speed training with boosters makes a difference

A 20-year follow-up of older adults in the ACTIVE randomized trial linked to Medicare claims found that speed of processing cognitive training with booster sessions was associated with a significantly lower risk of diagnosed Alzheimer’s disease and related dementias. Memory and reasoning training did not show comparable long-term reductions in dementia risk.

2 Mar 2026

Remote ischemic conditioning shields the heart from chemotherapy damage

Advances in cancer treatment mean that more people than ever are surviving the disease. However, some of the most effective anticancer drugs-a class of medicines called anthracyclines-can cause serious damage to the heart.

2 Mar 2026

Common cardio drugs proven safe in myeloma patients

Commonly prescribed cardiovascular medications—such as statins, diuretics, and blood pressure drugs—appear to have little or no negative impact on survival among people living with multiple myeloma, according to new international research.

1 Mar 2026

Blood biomarker guides bladder-sparing treatment decisions for cancer patients

Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence within the bladder, according to new data presented today by Fox Chase Cancer Center researchers.

27 Feb 2026

New approach to reducing radiation toxicity

Radiation therapy is highly effective at killing cancer cells, but it often harms healthy skin around the treatment area, a common side effect experienced by up to 95% of cancer patients undergoing treatment. In worst-case scenarios, it can result in delayed or halted treatment.

26 Feb 2026

Lymphovenous anastomosis may be an effective treatment for Alzheimer's disease

A small but growing body of evidence suggests that a minimally invasive surgical procedure called lymphovenous anastomosis (LVA) might be an effective treatment for Alzheimer's disease (AD), according to a special article in the March issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons (ASPS).

26 Feb 2026

Exercise during chemotherapy boosts breast cancer patients' quality of life

For many women with breast cancer, the very treatment that saves their lives can also bring fatigue, loss of muscle mass, emotional strain and other daunting obstacles.

26 Feb 2026

Financial toxicity in cancer care erodes hope and life satisfaction

Cancer treatment can take a profound financial toll, and new research shows the damage does not stop at the bank account.

26 Feb 2026

Next-generation CAR T therapy offers hope but faces clinical challenges

A new editorial perspective was published in Volume 17 of Oncotarget on February 20, 2026, titled "CAR-T therapy: Trailblazing CAR(ing) in cancer treatment."

25 Feb 2026

New EANM award supports alpha radioligand therapy research

Applications are now open for the 2026 EANM Young Scientist Network Award. This new research award, supported by Advanced Accelerator Applications (a Novartis company), aims to accelerate innovative research in alpha radioligand therapy (α-RLT) in prostate cancer.

23 Feb 2026

Ochsner MD Anderson Cancer Center delivers Louisiana’s first TIL therapy for melanoma

Ochsner MD Anderson Cancer Center at The Gayle and Tom Benson Cancer Center in New Orleans announces a milestone in advanced cancer treatment, as the first institution in Louisiana to provide an adult patient with tumor-infiltrating lymphocytes (TIL) therapy for advanced melanoma.

23 Feb 2026